Literature DB >> 31020235

Extensive intracardiac thrombi in a patient with heart failure and hepatic congestion: a case report.

Bernard Wong1, Timothy Glenie1, Eileen Merriman2, Colin Edwards1.   

Abstract

BACKGROUND: Left ventricular (LV) thrombi is a complication associated with anterior ST-elevation myocardial infarction, dilated cardiomyopathies, or LV aneurysms. Right sided intracardiac thrombi may be associated with other prothrombotic causes. CASE
SUMMARY: A 66-year-old man admitted with congestive heart failure was found to have extensive intracardiac masses on transthoracic echocardiography and cardiac magnetic resonance imaging (MRI). This occurred in the absence of a recent myocardial infarction. During his hospital stay, he was found to have deranged liver enzymes and coagulation profile due to hepatic congestion. The patient was presumed to have intracardiac thrombi and was treated with warfarin therapy. There was complete resolution of the masses on repeat cardiac MRI after 4 weeks of treatment, confirming the diagnosis. DISCUSSION: Cardiac MRI is useful in the diagnosis of intracardiac thrombi. Clinicians should appreciate the prothrombotic risks associated with liver disease, despite the inability of standard coagulation tests to quantify this risk.

Entities:  

Keywords:  Cardiac magnetic resonance imaging; Case report; Congestive cardiac failure; Intracardiac thrombi; Liver disease

Year:  2018        PMID: 31020235      PMCID: PMC6439363          DOI: 10.1093/ehjcr/yty159

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


Learning points

Right sided intracardiac thrombi should prompt the clinician to search for causes of hypercoagulability. T1- and T2-weighted sequences on cardiac magnetic resonance imaging may be useful to determine the age of intracardiac thrombi. Standard coagulation profiles do not measure the prothrombotic risk of patients with liver disease.

Introduction

Left ventricular (LV) thrombi are a complication associated with anterior ST-elevation myocardial infarction, dilated cardiomyopathies, or LV aneurysms. The incidence of LV thrombi has decreased in recent years with the improvement in primary reperfusion strategies, which decrease infarct size and the development of LV aneurysms. Unlike LV thrombi, the development of right heart thrombi is often precipitated by non-infarct causes, and they are morphologically heterogeneous. Type A thrombi are mobile, serpiginous and have a high association with deep vein thrombosis. Type B thrombi have a non-specific shape, are less mobile, and often resemble LV thrombi. Right heart thrombi have been reported in the presence of right ventricular (RV) pacemaker leads, right sided mechanical valves, and ventricular or atrial septal closure devices.,

Timeline

Case presentation

A 66-year-old man without any prior cardiac history presented to the hospital with a 1-month history of dyspnoea on exertion, orthopnoea, paroxysmal nocturnal dyspnoea, and 4 kg unintentional weight loss. On admission, he had a blood pressure of 103/81 mmHg, heart rate 90 b.p.m., respiratory rate 20 b.p.m., and an oxygen saturation of 98% on room air. Jugular venous pressure was elevated at +4 cm, and he had bilateral peripheral oedema to the knees. Auscultation revealed a pansystolic murmur at the apex with a third heart sound, and bilateral crackles at the lung bases. Initial laboratory tests showed an elevated N-terminal pro-brain natriuretic peptide [2056 pmol/L (reference range <35)] and normal troponin I [21 ng/L (reference range <40)]. Electrocardiogram showed sinus rhythm, left axis deviation, inferior Q-waves, and no ST changes. He was referred for transthoracic echocardiography which revealed dilated left and right ventricles. The LV internal diameter end diastole and systole were 64 mm and 61 mm, respectively, with a LV ejection fraction (LVEF) calculated by Simpson’s biplane method of 17%. There were moderate mitral and tricuspid regurgitation secondary to the dilated ventricles. The pulmonary artery systolic pressure was 34 mmHg, and the estimated mean right atrial pressure was 10–15 mmHg, as evidenced by an inferior vena cava (IVC) diameter of 17 mm which collapses less than 50% on inspiration. There were masses in both apices and two further masses in the right atrium suspicious for type B thrombi (Figure and Supplementary material online, Video S1). The cardiomyopathy and intracardiac masses were further analysed with cardiac magnetic resonance imaging (MRI) (Supplementary material online, Video S2), which showed the intracardiac masses had high signal intensity on T1- and T2-weighted sequences (Figure ). They were low-signal on first pass imaging following gadolinium administration. The LV and RV end-diastolic volumes were 385 mL and 305 mL, respectively. The calculated LVEF was 19% and RV ejection fraction (RVEF) 20% (). Additionally, there was evidence of fluid overload with small bilateral pleural effusions and an IVC diameter of 29 mm. Delayed enhancement sequences showed near full thickness scars in the lateral and inferior walls, consistent with prior myocardial infarctions (Figure ). Coronary angiography revealed severe triple vessel disease, including occlusion of the left circumflex and right coronary arteries. The presence of suspected right heart thrombi led to the investigation of hypercoagulable states. His weight loss raised the suspicion of underlying malignancy, but a subsequent computed tomography of his body and pulmonary angiogram was negative for malignancy or pulmonary embolism. His weight loss was therefore attributed to cardiac cachexia. Review of the admission blood work identified elevated liver enzymes; aspartate aminotransferase 106 U/L (reference range <45), alanine aminotransferase 406 U/L (reference range <45), gamma-glutamyl transferase 64 U/L (reference range <60), and hyperbilirubinemia 60 μmol/L (reference range <25). His coagulation profile revealed a prolonged prothrombin time [24 s (reference range 10–14)], prothrombin ratio [2.0 (reference range 0.8–1.2)], and activated partial thromboplastin time [43 s (reference range 25–38); which fully corrected with the addition of normal plasma]. It was likely that these derangements were due to hepatic congestion from his RV failure, as his abnormal liver enzymes and coagulation profile normalized following diuresis. The patient was started on warfarin with bridging enoxaparin, for the likely diagnosis of multiple intracardiac thrombi. Revascularization was postponed until resolution of the thrombi to avoid increased bleeding risk from triple antithrombotic therapy, due to risk of further hepatic congestion and coagulopathy. The patient was discharged home on warfarin, lisinopril 10 mg daily, frusemide 40 mg daily, and carvedilol 12.5 mg twice daily. He returned 1 month later for a follow-up MRI, which showed the LVEF was still significantly reduced at 22%, but the RVEF had improved to 46%. There was complete resolution of the all the intracardiac masses, therefore confirming the diagnosis of thrombi (Figure ). Unfortunately, the patient had an aborted out of hospital cardiac arrest shortly thereafter, which led to percutaneous coronary intervention to his left anterior descending artery, and subsequent insertion of an implantable cardiac defibrillator.
Table 1

Volume measurements of left and right ventricles on cardiac magnetic resonance imaging

Left ventricleRight ventricle
End diastolic volume385 mL (190 mL/m2)302 mL (149 mL/m2)
End systolic volume312 mL (154 mL/m2)242 mL (119 mL/m2)
Stroke volume73 mL (36 mL/m2)60 mL (30 mL/m2)
Ejection fraction19%20%
Volume measurements of left and right ventricles on cardiac magnetic resonance imaging Transthoracic echocardiography showing a mass in the apex of the left ventricle (A) and multiple masses (red arrows) in the right atrium and ventricle (B). Cardiac magnetic resonance imaging in four chamber views showing high intensity signal for the intracardiac masses on T1 (A) and T2-weighted (B) black blood sequences, suggestive of acute thrombi. First pass imaging following gadolinium administration showing lack of perfusion in the intracardiac masses (A). Delayed enhancement sequence in the short-axis view showing near full thickness scar in the lateral and inferior walls (B). First pass imaging following gadolinium administration after 1 month of warfarin therapy showing complete resolution of all intracardiac masses.

Discussion

Intracardiac thrombi are associated with morbidity and mortality related to embolization. Empiric anticoagulation in heart failure without other indications such as atrial fibrillation and prosthetic valves to reduce thromboembolism has been well studied. The WARCEF and COMMANDER HF trials showed no benefit for warfarin and rivaroxaban, respectively., T1 and T2 sequences on cardiac MRI may be helpful in differentiating the age of thrombi. Different signal intensities of thrombi on cardiac MRI has been linked with the age of haemoglobin degradation, with progressive loss of T1 and T2 signals as the thrombi becomes more organized. The presence of right heart thrombi, particularly in the right atrium, should prompt the clinician to search for prothrombotic conditions. These may include liver disease, sepsis, disseminated intravascular coagulation, or hereditary thrombophilia in younger patients. Liver disease is commonly associated with increased bleeding risk due to its effects on platelets and clotting factors. However, it is also associated with prothrombotic changes due to reduced production of endogenous inhibitors of coagulation such as protein C and antithrombin, while levels of factor VIII are elevated. Standard coagulation tests do not measure this prothrombotic risk, though it should be appreciated by clinicians when liver disease is present. Although the intracardiac thrombi cannot be linked directly to hepatic congestion in our patient, it occurred despite the impaired coagulation system associated with hepatic dysfunction, as supported by prolonged coagulation tests. This suggests that the combination of dilated cardiomyopathy and prothrombotic changes associated with hepatic dysfunction, resulted in a hypercoagulable state, which precipitated intracardiac thrombi formation. Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data. Consent: The authors confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidance. Conflict of interest: none declared. Click here for additional data file.
DateEvents
22 May 2018Presented with symptoms of biventricular heart failure. Transthoracic echocardiography showed biventricular dilatation with severe systolic dysfunction and multiple masses in both apices and the right atrium
24 May 2018Cardiac magnetic resonance imaging (MRI) showed ischaemic scars and confirmed intracardiac masses
01 June 2018Cardiac catheterization showed occluded left circumflex and right coronary arteries, and severe stenosis of the mid-left anterior descending artery
11 June 2018Discharged on warfarin and medical therapy for heart failure
28 June 2018Repeat cardiac MRI showed complete resolution of intracardiac masses
01 July 2018Out of hospital cardiac arrest, admitted to intensive care unit
05 July 2018Percutaneous coronary intervention to left anterior descending artery
06 July 2018Implantable cardioverter defibrillator inserted
11 July 2018Patient discharged home
  11 in total

1.  Right atrial thrombus following closure of an atrial septal defect.

Authors:  M Yilmaz; Y Gurlertop; F Erdogan
Journal:  Heart       Date:  2003-07       Impact factor: 5.994

2.  Right heart thrombi: consider the cause.

Authors:  Gordon N Finlayson
Journal:  Can J Cardiol       Date:  2008-12       Impact factor: 5.223

Review 3.  Hypercoagulability in cirrhosis: causes and consequences.

Authors:  A Tripodi; Q M Anstee; K K Sogaard; M Primignani; D C Valla
Journal:  J Thromb Haemost       Date:  2011-09       Impact factor: 5.824

4.  Left Ventricular Thrombus Formation After ST-Segment-Elevation Myocardial Infarction: Insights From a Cardiac Magnetic Resonance Multicenter Study.

Authors:  Janine Pöss; Steffen Desch; Charlotte Eitel; Suzanne de Waha; Holger Thiele; Ingo Eitel
Journal:  Circ Cardiovasc Imaging       Date:  2015-10       Impact factor: 7.792

5.  Warfarin and aspirin in patients with heart failure and sinus rhythm.

Authors:  Shunichi Homma; John L P Thompson; Patrick M Pullicino; Bruce Levin; Ronald S Freudenberger; John R Teerlink; Susan E Ammon; Susan Graham; Ralph L Sacco; Douglas L Mann; J P Mohr; Barry M Massie; Arthur J Labovitz; Stefan D Anker; Dirk J Lok; Piotr Ponikowski; Conrado J Estol; Gregory Y H Lip; Marco R Di Tullio; Alexandra R Sanford; Vilma Mejia; Andre P Gabriel; Mirna L del Valle; Richard Buchsbaum
Journal:  N Engl J Med       Date:  2012-05-02       Impact factor: 91.245

6.  Right atrial thrombus and its causes, complications, and therapy.

Authors:  Mina M Benjamin; Aasim Afzal; Themistokles Chamogeorgakis; Georges A Feghali
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-01

7.  Incidence and outcomes of early left ventricular thrombus following ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.

Authors:  Shafik Khoury; Sarit Carmon; Gilad Margolis; Gad Keren; Yacov Shacham
Journal:  Clin Res Cardiol       Date:  2017-04-10       Impact factor: 5.460

8.  Magnetic resonance imaging evaluation of cardiac masses.

Authors:  Maria Fernanda Braggion-Santos; Marcel Koenigkam-Santos; Sara Reis Teixeira; Gustavo Jardim Volpe; Henrique Simão Trad; André Schmidt
Journal:  Arq Bras Cardiol       Date:  2013-07-26       Impact factor: 2.000

Review 9.  Left ventricular thrombus formation after acute myocardial infarction.

Authors:  Ronak Delewi; Felix Zijlstra; Jan J Piek
Journal:  Heart       Date:  2012-12       Impact factor: 5.994

10.  Clinical Characteristics and Risk Factors of Left Ventricular Thrombus after Acute Myocardial Infarction: A Matched Case-control Study.

Authors:  Yue-Xin Jiang; Lin-De Jing; You-Hong Jia
Journal:  Chin Med J (Engl)       Date:  2015-09-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.